Stephanie Charles, MD
Endocrinology · West Nyack, NYNPI 1588012413
Payments from drug & device makers
Across 565 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Corcept Therapeutics$1K
- Novo Nordisk$1K
- Lilly USA, LLC$977
- Mannkind Corporation$713
- Sanofi-aventis U.S. LLC$656
- plus $4K from 25 others
What the payments were for
- Food & beverage$10,18499%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 54 | $1,445 |
| Corcept Therapeutics | 54 | $1,260 |
| Novo Nordisk | 58 | $1,113 |
| Lilly USA, LLC | 66 | $977 |
| Mannkind Corporation | 97 | $713 |
| Sanofi-aventis U.S. LLC | 24 | $656 |
| Xeris Pharmaceuticals, Inc. | 26 | $584 |
| Boehringer Ingelheim | 27 | $545 |
| AstraZeneca(2 entities) | 21 | $481 |
| Abbott | 20 | $358 |
| Medtronic | 18 | $345 |
| Recordati_rare_diseases_inc. | 17 | $329 |
| AbbVie | 16 | $329 |
| Radius Health, Inc. | 16 | $195 |
| Ascendis Pharma Endocrinology Inc | 7 | $142 |
| Amneal Pharmaceuticals LLC | 6 | $111 |
| Alvogen Inc | 5 | $104 |
| Merck | 7 | $101 |
| Embecta Corp. | 4 | $91 |
| Pfizer | 3 | $73 |
| Ultragenyx Pharmaceutical Inc. | 4 | $66 |
| Endo Pharmaceuticals Inc. | 3 | $49 |
| GSK | 2 | $47 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Averitas Pharma Inc. | 2 | $30 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Halozyme Inc | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| IBSA Pharma Inc. | 1 | $15 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,275 in reported general payments places this provider in the 90th percentile of 64 endocrinology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 430 | $687,942 |
| JardianceEmpagliflozin | 171 | $242,330 |
| MounjaroTirzepatide | 147 | $208,809 |
| TrulicityDulaglutide | 124 | $206,372 |
| FarxigaDapagliflozin Propanediol | 108 | $145,027 |
| TymlosAbaloparatide | 18 | $127,534 |
| ForteoTeriparatide | 14 | $69,766 |
| JanuviaSitagliptin Phosphate | 40 | $53,392 |
| Tresiba Flextouch U-100Insulin Degludec | 40 | $31,847 |
| TradjentaLinagliptin | 22 | $30,179 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $20,688 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $18,803 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $16,800 |
| SynthroidLevothyroxine Sodium | 244 | $15,940 |
| Novolog FlexpenInsulin Aspart | 43 | $12,300 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,113 | $694,783448 claims |
| Lilly USA, LLCMounjaro, Trulicity, Forteo | $977 | $484,947285 claims |
| Boehringer IngelheimJardiance, Tradjenta | $545 | $272,510193 claims |
| AstraZenecaFarxiga | $481 | $145,027108 claims |
| Radius Health, Inc.Tymlos | $195 | $127,53418 claims |
| MerckJanuvia, Janumet Xr | $101 | $74,08053 claims |
| AbbVieSynthroid | $329 | $15,940244 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $111 | $11,714580 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 64 endocrinology providers in New York.
Other endocrinology in West Nyack
- Philip RabitoNew York$712K
- Perry HersonWilliston Park$364K
- Olga LeonardiNew York$10K
- Isabela RomaoNew Hyde Park$10K
- Sanjay SahayGarden City$9K
- Norma QuijadaOrchard Park$8K
- Swaminathan GiridharanBrooklyn$7K
- Julia KaplunSuffern$6K
- Elia KassabBrooklyn$1K
- Lauren GoldenNew York$729
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.